Boosting ADR Reporting: Assessing Knowledge, Attitude, and Practices Among UAE Hospital Pharmacists

By HEOR Staff Writer

August 2, 2023

A recent study aimed to evaluate the knowledge, attitudes, and practices (KAP) of hospital pharmacists in the UAE regarding Adverse Drug Reaction (ADR) reporting and the barriers to implementing a Pharmacovigilance (PV) system.

Although pharmacists generally display a positive attitude towards ADR reporting, the level of reporting remains low, which may be due to a lack of knowledge about PV and ADRs, including what, where, and when to report.

Interestingly, findings showed that gender does not affect awareness of PV and ADR reporting, but educational level and years of experience do. Hospital pharmacists with less than five years of experience lack the expertise of those with 10-14 years of experience in PV and ADR reporting.

Despite observing ADRs, only half of the participants reported them. This underreporting could be due to poor time management, lack of awareness of the reporting process, difficulties in accessing ADR reports, and poor patient-pharmacist communication.

They also found that the role and years of experience influence the likelihood of ADR reporting. Clinical pharmacists and inpatient pharmacists are more likely to engage in PV due to their direct patient care experience.

In terms of barriers, over half of the pharmacists cited a lack of knowledge about the reporting process. Fear of repercussions from management and legal culpability were also mentioned.

To improve ADR reporting, they recommend incentives for reporting, conducting workshops and ongoing education, providing legal protection, and ensuring easy online access to ADR forms.

Reference url

Recent Posts

AI Regulatory Research Priorities
AI Regulatory Research Priorities in Medicine Lifecycle Management

By João L. Carapinha

June 12, 2026

AI Regulatory Research Priorities have crystallised around one central requirement: establishing trustworthy performance of artificial intelligence systems across the entire pharmaceutical development and evaluation pathway. Stakeholders from every corner of the European medicines regulatory netw...
gene therapy reimbursement
Gene Therapy Reimbursement Strategies for Vision Restoration

By HEOR Staff Writer

June 12, 2026

Gene therapy reimbursement in the Netherlands has demonstrated clear clinical value since the 2021 conditional access agreement for voretigene neparvovec (Luxturna®). Five years of structured real-world use confirmed that carefully designed protocols successfully selected appropriate patients wit...
Insulin Cost Policy Impact
Insulin Cost Policy Impact on Medicare Beneficiaries

By HEOR Staff Writer

June 8, 2026

The Insulin Cost Policy Impact became clear in 2023 after the Inflation Reduction Act limited out-of-pocket insulin expenses to $35 per 30-day supply for Medicare Part D beneficiaries. According to a JAMA Network study, the c...